Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in ...
On October 12, 2026, Bristol Myers Squibb (BMS) announced that it had achieved primary endpoints in two Phase 3 trials. One ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results